Subscribe To
Predicine announces new study published in the new england journal of medicine demonstrating clinical utility of its mrd liquid biopsy assay in supporting genentech’s phase 1 clinical trial of divaras
PredicineBEACON™ and PredicineWES+™ were used to detect and monitor a diverse spectrum of genomic alternations and emerging resistance mechanisms ...
September 20, 2023, 5:12 pm
Predicine announces new study published in the new england journal of medicine demonstrating clinical utility of its mrd liquid biopsy assay in supporting genentech’s phase 1 clinical trial of divaras
PredicineBEACON™ and PredicineWES+™ were used to detect and monitor a diverse spectrum of genomic alternations and emerging resistance mechanisms ...
September 20, 2023, 5:12 pm
Predicine announces new study published in the new england journal of medicine demonstrating clinical utility of its mrd liquid biopsy assay in supporting genentech’s phase 1 clinical trial of divaras
PredicineBEACON™ and PredicineWES+™ were used to detect and monitor a diverse spectrum of genomic alternations and emerging resistance mechanisms ...
September 20, 2023, 5:12 pm
Onkure therapeutics appoints ann howell, pharm.d., as vice president of regulatory affairs
BOULDER, Colo., Sept. 20, 2023 (GLOBE NEWSWIRE) — OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next gener...
September 20, 2023, 1:41 pm
Global generic injectables market is anticipated to reach us$ 307.7 billion by 2031, rising at a 12.3% cagr: tmr report
The expansion of telemedicine services has increased the need for accessible injectable medications, pr...
September 20, 2023, 1:16 pm
Veru to participate in fireside chat at the 2023 cantor fitzgerald global healthcare conference on september 28th, 2023
MIAMI, FL, Sept. 20, 2023 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel m...
September 20, 2023, 12:30 pm
Exscientia stock surges on merck kgaa partnership
Exscientia PLC shares climbed as much as 30% in pre-market trading on Wednesday after the precision-medicine <...
September 20, 2023, 9:13 am
Newamsterdam pharma to present at 2023 cantor fitzgerald global healthcare conference
NAARDEN, The Netherlands and MIAMI, Sept. 20, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or ...
September 20, 2023, 8:00 am
Exscientia's stock rockets toward a record gain after ai-driven drug discovery collaboration with germany's merck kgaa
The U.S.-listed shares of Exscientia PLC EXAI soared 28.5% toward a record one-day gain, and enough to pace all premarket gainers on major U.S. exchan...
September 20, 2023, 7:50 am
Ovid therapeutics to present at the 2023 cantor fitzgerald global healthcare conference
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that...
September 20, 2023, 7:30 am
Astrazeneca rises on completion of pfizer gene therapy deal
AstraZeneca PLC (LSE:AZN) shares rose 2.4% to 10,868p after its Alexion rare disease unit sealed a deal to buy a portfolio of Pfizer's early-stage...
September 20, 2023, 4:31 am
Genflow biosciences primed and ready for phase i/ii trial after regulatory sign-off
Genflow Biosciences PLC (LSE:GENF, OTC:GENFF) said it has received encouraging advice from Belgium's Federal Agency for Medicines and Health Products ...
September 20, 2023, 3:24 am
Acrivon therapeutics to highlight its acr-368 oncosignature test, used in ongoing phase 2 study to treat patients based on predicted sensitivity to monotherapy with its chk1/2 inhibitor acr-368, at th
WATERTOWN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) — Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clini...
September 19, 2023, 8:32 pm
Bruker (brkr) advances novel 4d-proteomics capabilities
Bruker's (BRKR) commitment to innovation and customer support makes it a great partner and helps achieve its mission of translating nature into medici...
September 19, 2023, 2:17 pm
Pfizer stock: bear vs. bull
Pfizer is planning to acquire businesses and assets to power its growth. It'll be fighting against falling coronavirus ...
September 19, 2023, 10:07 am
2 cutting-edge gene-editing stocks that you don't want to miss
Gene-editing therapies are among the most powerful medicines to ever exist. Wave Life Sciences is taking aim at two rare diseases, but it's short on c...
September 19, 2023, 9:37 am
Annexon biosciences to participate in the 2023 cantor global healthcare conference
BRISBANE, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class o...
September 19, 2023, 6:30 am
Relay therapeutics to present clinical data on rly-4008 in advanced fgfr2-altered solid tumors at 2023 aacr-nci-eortc international conference on molecular targets and cancer therapeutics
CAMBRIDGE, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision ...
September 18, 2023, 4:05 pm
Vigil neuroscience: interesting early data, wait for phase 2
Vigil Neuroscience is developing medicines for neurodegenerative diseases by restoring microglial function. Their lead candidate, VGL101, is a monoclo...
September 18, 2023, 2:38 pm
Cellectar biosciences receives european medicines agency priority medicines (prime) designation for iopofosine for waldenstrom’s macroglobulinemia
The EMA’s PRIME status is granted to drug candidates that may offer a major therapeutic advantage over existing treatments, or benefit patients with...
September 18, 2023, 12:40 pm